Cigarette Smoking and Treatment Outcomes in Graves Ophthalmopathy

作者：Luigi Bartalena, Claudio Marcocci, Maria Laura Tanda, Luca Manetti, Enrica Dell'Unto, Maria Pia Bartolomei, Marco Nardi, Enio Martino, Aldo Pinchera · 发表于：Annals of Internal Medicine · 年份：1998 · DOI：10.7326/0003-4819-129-8-199810150-00010 · 被引用次数：296 · 研究领域：Ophthalmology and Eye Disorders、Ocular Oncology and Treatments、Glaucoma and retinal disorders

BACKGROUND: It is unclear whether smoking affects the course of Graves ophthalmopathy and therapeutic outcomes. OBJECTIVE: To observe smoking behavior in a randomized study of the effect of radioiodine therapy on ophthalmopathy and in a case series of patients with Graves ophthalmopathy receiving orbital radiation therapy and glucocorticoids. DESIGN: Randomized, single-blind study of smoking and mild ophthalmopathy after radioiodine therapy (study 1) and a retrospective cohort study of the association between smoking and response of severe ophthalmopathy to treatment (study 2). SETTING: University medical center. PATIENTS: 300 patients with mild ophthalmopathy (study 1) and 150 patients with severe ophthalmopathy (study 2). INTERVENTION: In study 1, patients received radioiodine alone or radioiodine and a 3-month course of oral prednisone (initial dosage, 0.4 to 0.5 mg/kg of body weight per day). In study 2, patients received high-dose oral prednisone for 6 months (initial dosage, 80 to 100 mg/d) and underwent orbital radiation therapy by linear accelerator (cumulative dose, 20 Gy per eye over 2 weeks). MEASUREMENTS: Degree of ophthalmopathy was assessed by overall evaluation (inflammatory changes, proptosis, extraocular muscle dysfunction, corneal involvement, and optic neuropathy). RESULTS: In study 1, ophthalmopathy progressed in 4 of 68 nonsmokers (5.9% [95% CI, 3% to 9%]) and 19 of 82 smokers (23.2% [CI, 13% to 33%]) who received radioiodine alone (P = 0.007). Ophthalmop...